Heart Failure Hospitalisation: An opportunity to reset chronic therapy with Entresto?
|
|
- Abigail Ellis
- 5 years ago
- Views:
Transcription
1 Heart Failure Hospitalisation: An opportunity to reset chronic therapy with Entresto? Mark C Petrie Professor of Cardiology Honorary Consultant Cardiologist BHF Glasgow Cardiovascular Research Centre Glasgow Royal Infirmary and Golden Jubilee National Hospital Glasgow
2 Disclosures Speakers fees and consultancy fees Boehringer Ingelheim, Servier, Novartis, Maquet, Takeda, Astra, Daiichi Sankyo, Novo Nordisk, SC Pharmaceuticals, Corvia, Pfizer, Vifor, Pharmacosmos Member of Clinical Events Committees Boehringer Ingelheim, GSK, Astellas, Roche, Bayer, Cardiorentis, Reverslogix, Astra Zeneca, Stealth Pharmaceuticals, Novartis, Abbott, Abbvie
3 Disclaimer The following presentation may contain scientific / medical information on unapproved products/ dosages / indications currently under clinical investigation and/or regulatory review. Kindly note that the views and opinions of the speaker do not necessarily reflect those of Novartis. Novartis South Africa (Pty) Ltd recommends the use of their products in accordance with the locally approved Package Insert.
4 South African Indication for Entresto ENTRESTO is indicated as a second-line therapy, replacing ACE inhibitors or ARB for treatment of symptomatic heart failure (NYHA class II-IV) in patients with systolic dysfunction. ENTRESTO is administered in combination with other heart failure therapies as appropriate.
5 Admitted on: enalapril 7.5mg BD, carvedilol 25mg BD,spironolactone 50mg, furosemide 80mg A recent case Female AG Age 69 Known DCM for 8 years, CRTD 2014 Diabetes, COPD Hospitalised for the first time with DCM EF 36%, NT-BNP 800,
6 A recent case HR 94 BP 100/58 Oedema to knees Crackles bibasally JVP elevated to jaw
7 A recent case egfr 34; K 5.2 Hb 110 Ferritin 50; T sats 13% IV diuretics IV iron
8 A recent case Stablised HR 75, BP 110/62, euvolaemic Do you want to change her drug therapy? enalapril 7.5mg BD, carvedilol 25mg BD, spironolactone 50mg, furosemide 80mg
9 Thirty years of progress in HF-REF Positive drug trials
10 Thirty years of progress in HF-REF Positive drug, device and other trials PARADIGM
11 HF-REF: Where we were until recently Digoxin CABG Tx VAD CRT ICD Ivabradine H-ISDN Beta-blocker ACEi/ARB MRA ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft surgery; CRT, cardiac resynchronisation therapy; HF-REF, heart failure with reduced ejection fraction; H-ISDN, hydralazine/isosorbide dinitrate; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid (aldosterone) receptor antagonist; VAD, ventricular assist device McMurray et al. Eur Heart J 2012;33:
12 Sacubitril/valsartan: First in class dual-acting angiotensin receptor neprilysin inhibitor ARNi LCZ696 is a crystalline complex comprised of 6 valsartan moieties, 6 sacubitril (AHU377) moieties, sodium cations, and water held together by network of hydrogen bonds
13 What does sacubitril/valsartan do? Valsartan angiotensin receptor blocker Blocks angiotensin II effects - sodium and water retention - cardiac fibrosis/ hypertrophy - vasoconstriction
14 What does sacubitril/valsartan do? Valsartan angiotensin receptor blocker Blocks angiotensin II effects - sodium and water retention - cardiac fibrosis/ hypertrophy - vasoconstriction BOND Sacubitril neprilysin inhibitor
15 What does sacubitril/valsartan do? Valsartan angiotensin receptor blocker BOND Sacubitril neprilysin inhibitor Blocks angiotensin II effects - sodium and water retention - cardiac fibrosis/ hypertrophy - vasoconstriction Inhibits breakdown of good peptides(bnp, ANP, bradykinin ) - Vasodilatation - Inhibition of cardiac fibrosis/ LVH - Natriuresis/diuresis
16 Cumulative Proportion of Patients with Primary End Point (%) PARADIGM-HF: Primary outcome HR: 0.80 (0.73, 0.87) p = Enalapril 1117 (n=4212) sac/val (n=4187) Days after Randomization At risk enalapril: sac/val: McMurray, Packer et al. N Engl J Med 2014; 371(11):
17 Cumulative Proportion of Patients Who Died from Any Cause (%) PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial Death from any cause 16% risk reduction 40 HR: 0.84 (0.76, 0.93) P = enalapril (n=4212) sac/val (n=4187) Days after Randomization
18 Reducing HF mortality Mortality with in 2017 HF treatment
19 PARADIGM-HF: Percentage of patients with at least 5 points deterioration in KCCQ scores at month 8 % Physical limitation Symptom stability Symptom frequency Symptom burden LCZ696 (N=3833) Total symptom score Enalapril (N=3873) P=0.004 P=0.029 P<0.001 P<0.005 P<0.001 P<0.001 P=0.001 P=0.001 P<0.001 P<0.001 Self efficacy Quality of life Social limitation Overall summary score Clinical summary score Clinical summary score based on the physical limitation and total symptom score domains. Death imputed as zero. The analysis included all patients with at least one KCCQ data point
20 Mortality All-cause mortality (%) after a HF hospitalisation (%) % 32.1% 30.8% 37.3% Okumura et al. Circulation : No event (993/6853) Intensifica on of therapy (116/361) Emergency department visit (24/78) Heart failure hospitaliza on (413/1107)
21 PARADIGM-HF Death from CV causes 20% risk reduction HF hospitalization 21% risk reduction P = P = McMurray, Packer et al. N Engl J Med 2014; 371(11):
22 Recurrent HF hospitalizations Mogensen et al. Circulation 2016; 134(Supl1): A19644
23 Recurrent HF hospitalizations Mogensen et al. Circulation 2016; 134(Supl1): A19644
24 The 2016 ESC guidelines ACEI/ARB + BB + MRA ARNI CRT=cardiac resyncronization therapy; H-ISDN=hydralazine and isosorbide dinitrate; HR=heart rate; ICD=implantable cardioverter defibrillator; LVAD=left ventricular assist device; MR=mineralocorticoid receptor; OMT=optimal medical therapy; VT/VF=ventricular tachycardia/ventricular fibrillation Ponikowski et al. Eur Heart J 2016;37:
25 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
26 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
27 EF <35% or <40%?
28 Sacubitril/valsartan was effective across the spectrum of ejection fraction * >2000 patients with EF between 35 and 40% Solomon et al. Circ Heart Fail Mar;9(3):e002744
29 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
30 NYHA Class IV in PARADIGM-HF Sacubitril/valsartan better NYHA IV 0.71 (0.30, 1.69) Enalapril better Overall trial 0.80 (0.73, 0.87) Sacubitril/valsartan n/n (%) Enalapril n/n (%) Risk Ratio Sacubitril/valsartan vs. Enalapril NYHA IV Overall Safety Hypotension 3/33 (9.1) 3/27 (11.1) 0.95 (0.19, 4.69) 1.39 (1.26, 1.52) Renal impairment 4/33 (12.1) 3/27 (11.1) 1.25 (0.28, 5.60) 0.90 (0.81, 1.00) Hyperkalemia 5/33 (15.2) 6/27 (22.2) 0.71 (0.22, 2.32) 0.81 (0.72, 0.91) McMurray et al. Circulation 2016; 134(Supl1): A20000
31 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
32 Raised NT-proBNP / BNP or not?
33 Zile et al J Am Coll Cardiol Dec 6;68(22): Effect of sacubitril/valsartan vs enalapril by NT-proBNP
34 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
35 Diabetes
36 Diabetes under-diagnosed in PARADIGM-HF Undiagnosed diabetes 13% 36% Diagnosed diabetes Pre-diabetes 25% 26% Normal Circ Heart Fail. 2016;9:e002560
37 Sac/val versus enalapril and HBA1c Seferovic et al Lancet Diabetes Endocrinol 2017;5:
38 Sac/val versus enalapril: CV outcomes in DM and no DM CV end point HF hosps or CV death No DM HR (95% CI) 0.68 ( ) Pre-DM HR (95% CI) 0.76 ( ) Undiagnosed DM HR (95% CI) 0.97 ( ) DM HR (95% CI) 0.87 ( ) Interaction p value 0.13 CV death 0.62 ( ) 0.76 ( ) 0.86 ( ) 0.92 ( ) 0.09 HF hosps 0.85 ( ) 0.73 ( ) 0.88 ( ) 0.79 ( ) 0.78 All-cause mortality 0.68 ( ) 0.77 ( ) 0.91 ( ) 0.97 ( ) 0.06 Circ Heart Fail. 2016;9:e002560
39 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
40 Efficacy or sac/val versus enalapril with and without renal dysfunction CV Endpoints CKD (n=2745) HR (95% CI) No CKD (n=5654) HR (95% CI) Interaction p value CV death or HF hosps 0.79 ( ) 0.81 ( ) 0.70 CV death 0.76 ( ) 0.84 ( ) 0.39 HF hosps 0.79 ( ) 0.81 ( ) 0.83 All-cause mortality 0.79 ( ) 0.89 ( ) 0.27 JACC Heart Fail 2018 Jun;6(6):
41 Sac/val versus enalapril: Mean change in egfr from baseline JACC HF 2008;6:489-98
42 Renal progression: Protocol-defined endpoint 50% decline in egfr >30 ml/min/1.73m 2 decline in egfr to <60 ml/min/1.73m 2 Reaching ESRD
43 Renal progression: Protocol-defined endpoint Endpoint Composite Hazard Ratio (95% CI) P- value 0.86 (0.65, 1.13) (i) 50% decline in egfr 0.75 (0.47, 1.19) (ii) >30 ml/min/1.73m 2 decline in egfr to <60 ml/min/1.73m (0.80, 1.53) (iii) Reaching ESRD 0.50 (0.21, 1.16) JACC HF 2008;6:489-98
44 Renal progression: Conventional renal endpoint (post-hoc analysis) Endpoint Hazard Ratio (95% CI) P Value 2-sided Composite 0.63 (0.42, 0.95) (i) 50% decline in egfr 0.75 (0.47, 1.19) (iii) Reaching ESRD 0.50 (0.21, 1.16) JACC HF 2008;6:489-98
45 PARADIGM-HF: Adverse events leading to permanent study drug discontinuation (%) Any adverse event p = 0.03 Enalapril 29 Hypotension p = 0.38 Sacubitril/valsartan Renal reasons p = Hyperkalaemia p = 0.56 McMurray et al. N Engl J Med 2014;371:
46 PARADIGM-HF: Renal safety (%) Enalapril Sacubitril/valsartan P= P=0.007 P=0.007 P= Cr 2.5 mg/dl Cr 3.0 mg/dl K+ > 5.5 mmol/l K+ > 6.0 mmol/l (221 µmol/l) (265 µmol/l) McMurray et al. N Engl J Med 2014;371:
47 Sac/val v enalapril renal summary Reduction in CV outcomes for sac/val versus enalapril is consistent for those with and without CKD Sac/ val slows decline in egfr>enalapril Less decline in composite of egfr>50% and ESRD with sac/val v enalapril Fewer discontinuations for renal reasons with sac/val than enalapril
48 Why might you not change to sacubitril/valsartan? Too old EF not low enough NYHA IV NT-BNP not high enough Diabetes Renal function Hyperkalaemia
49 Frailty and the elderly
50 rate per 100 patient years rate per 100 patient years rate per 100 patient years rate per 100 patient years Do the elderly benefit from sac/val versus enalapril? CV death or HF hospitalization < Age (years) CV death < Age (years) HF hospitalization All-cause death < Age (years) 0 < Age (years) Eur Heart J. 2015;36:
51 Sac/val versus enalapril: renal safety by age P for interaction >0.05 for all events <55 years years years 75 years Jhund et al. Eur Heart J. 2015;36:
52 Blood pressure
53 PARADIGM-HF: Systolic BP JACC Heart Fail Jun;6(6):
54 CV outcomes according to baseline systolic BP Primary endpoint Cardiovascular death Bohm et al Eur Heart J Feb 1. doi: /eurheartj/ehw570.
55 PARADIGM-HF: Adverse events leading to permanent study drug discontinuation (%) Any adverse event p = 0.03 Enalapril 29 Hypotension p = 0.38 Sacubitril/valsartan Renal reasons p = Hyperkalaemia p = 0.56 McMurray et al. N Engl J Med 2014;371:
56 Remember sudden death is common
57 The natural history of HF Diagnosis Progressive pump failure Adapted from Goodlin SJ. J Am Coll Cardiol. 2009;54(5):386-96
58 The natural history of HF SCD SCD SCD SCD Diagnosis Progressive pump failure Adapted from Goodlin SJ. J Am Coll Cardiol. 2009;54(5):386-96
59 The two major modes of death in HF Sudden death Death due to worsening HF Desai et al. Eur Heart J 2015;36:1990-7
60 Effect of sacubitril/valsartan on the two major modes of death in HF Sudden death Death due to worsening HF Enalapril HR=0.80 (0.68, 0.94) P=0.008 Sacubitril /valsartan HR=0.79 (0.64, 0.98) P=0.034 Enalapril Sacubitril /valsartan Sacubitril/ valsartan Sacubitril/ valsartan Desai et al. Eur Heart J 2015;36:1990-7
61 The clock is ticking 763 of 2309 (33%) of first primary endpoints were CV deaths 467 of these 763 deaths (61%) were sudden McMurray et al. N Eng J Med 2014;371: ; Desai As et al Eur Heart J. 2015;36:
62 Cumulative Proportion of Patients with Primary End Point (%) PARADIGM-HF: Primary outcome Cardiovascular death or heart failure hospitalization HR: 0.80 (0.73, 0.87) p = Enalapril 1117 (n=4212) 914 By 2030 days 0.65 ( 0.45, 0.93) P= Sacubitril/valsartan (n=4187) Days after Randomization At risk Enalapril: Sacubitril/valsartan: McMurray, Packer et al. N Engl J Med 2014; 371(11):
63 Benefit on top of other therapies
64 Incremental benefits of sacubitril/valsartan: CV death Diuretics Digoxin MRA ICD/CRT-D Prior coronary revascularization Number HR 95% CI No Yes No Yes No Yes No Yes No Yes Interaction P value Okumura et al Circ Heart Fail Sep;9(9). pii: e
65 Incremental benefits of sacubitril/valsartan according to background β-blocker use Cardiovascular death or HF hospitalization Number Interaction P value HR 95% CI Beta-blocker Beta-blocker % target dose No Yes <50% % Okumura et al Circ Heart Fail Sep;9(9). pii: e
66 De-mystify initiation
67 How to sacubitril/valsartan Population with HF-REF No patient characteristics requiring caution or dose reduction Currently only able to tolerate a low or submaximal target dose of ACEI or ARB* No ACEI or ARB in the past egfr <30 ml/min/m 2 ** Moderate hepatic impairment (Child Pugh Class B) Elderly Starting dose of sacubitril/valsartan 49/51 mg BID 24/26 mg BID 24/26 mg BID 24/26 mg BID 24/26 mg BID 24/26 mg BID Up titration and target dose Up titration by doubling of dose every 2 4 weeks until a target dose of 97/103 mg BID is reached *Target doses of ACE inhibitors and ARBs are: ACE inhibitors captopril 50 mg TID, enalapril 10 mg BID, lisinopril 20 mg OD, ramipril 5 mg BID, trandolopril 4 mg OD; ARBs candesartan 32 mg OD, losartan 150 mg OD, valsartan 160 mg OD **The European Medicines Agency also suggests that a dose of 24mg/26mg can be considered if egfr ml/min/m 2 Jhund and McMurray. Heart 2016;102:
68 How to ACEI /ARB Check renal function and electrolytes. Double the dose at not less than 2-week intervals in the community (can be done more rapidly in patients in hospital or who are otherwise closely monitored, tolerability permitting). Re-check blood chemistry 1-2 weeks after initiation and 1-2 weeks after dose titration Monitor blood chemistry 4 monthly thereafter Ponikowski P et al. Eur Heart J. 2016;37:
69 How to sac/val Check renal function and electrolytes. Double the dose at not less than 2-week intervals in the community (can be done more rapidly in patients in hospital or who are otherwise closely monitored, tolerability permitting). Re-check blood chemistry 1-2 weeks after initiation and 1-2 weeks after dose titration Monitor blood chemistry 4 monthly thereafter Ponikowski P et al. Eur Heart J. 2016;37:
70 What should I do if the patient experiences a side effect?
71 How to ACEI /ARB Asymptomatic low blood pressure: Does not usually require any change in therapy. Symptomatic hypotension: Dizziness/light headedness is common and often improves with time patients should be reassured. Reconsider need for nitrates, calcium-channel blockers and other vasodilators and reduce dose/stop, if possible. If no signs or symptoms of congestion, consider reducing diuretic dose. Ponikowski P et al. Eur Heart J. 2016;37:
72 Admitted on: enalapril 7.5mg BD, carvedilol 25mg BD,spironolactone 50mg, furosemide 80mg A recent case Female AG Age 69 Known DCM for 8 years, CRTD 2014 Diabetes, COPD Hospitalised for the first time with DCM EF 36%, NT-BNP 800,
73 Back to the case Sacubitril/ valsartan 24/26mg BD
74 Progress HF clinic Seen by heart failure nurses Generally keeping well No PND, no orthopnea, trace of oedema around ankles, JVP 4 cmh 2 O, BP 108/64 Bloods Sodium 136 mmol/l Potassium 5.1 mmol/l Urea 11 mmol/l Creatinine 105 µmol/l egfr 60 NAU2018AU134868
75 Progress HF clinic Uptitrated to sacubitril/valsartan 49/51mg BD NAU2018AU134868
76 Progress HF clinic Uptitrated to sacubitril/valsartan 49/51mg BD Bloods after uptitration Sodium 129 mmol/l Potassium 5.5 mmol/l Urea 16 mmol/l Creatinine 155 µmol/l egfr 38 BP 82/60 Feels dizzy especially on standing NAU2018AU134868
77 Progress HF clinic Eplerenone 25 mg OD Warfarin Carvedilol 25 mg BD Furosemide 80 mg BD Sacubitril/valsartan 49/51 mg BD NAU2018AU134868
78 Progress HF clinic Eplerenone 25 mg OD Warfarin Carvedilol 25 mg BD Furosemide 80 mg BD Furosemide 80 mg OD Sacubitril/valsartan 49/51 mg BD NAU2018AU134868
79 Current status NYHA II Trace of odema Renal function egfr 58 BP 97/64 no symptoms sacubitril/valsartan 97/103mg BD eplerenone 50mg OD carvediolol 25mg BD furosemide 40mg OD and warfarin NAU2018AU134868
80 Is initiation as an inpatient feasible? TRANSITION trial N =1002 pts hospitalised with HF Randomised to inpatient v outpatient initiation of sac/val. Pry end point proportion on 200mg BD sac/val at 10 weeks. Outcome 45% pre-discharge v 50% post-discharge on 200mg BD (HR % CI ) No difference in AEs or SAEs (ie well-tolerated) eg hypotension and hyperkalaemia <1.0%
81 Don t forget the outpatient who looks stable
82 Background JM 68 year old man Myocardial infarction 2006 Heart failure 2014 Reduced ejection fraction (32%) Not felt suitable for CABG Medical therapy optimised Implantable cardioverter defibrillator 2015 NAU2018AU134868
83 Background Feb 2016 NYHA class II SOB on stairs and hills Treated with: Enalapril 5mg BD Carvedilol 25mg BD Eplerenone 25mg OD Furosemide 80mg BD Warfarin NAU2018AU134868
84 Do we need anything more?
85 My patient seems to be stable My patient is low risk
86 EMPHASIS-HF Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure 2737 patients, 55 years, NYHA class II, with CV hospitalization within 6 months (or elevated BNP/NT pro BNP) and LVEF 0.30 (or 0.35 if QRS duration >130msec). Followed for a median of 21 months >25% of patients with MILD symptoms experience CV death or HF hospitalization within 3 years Zannad, McMurray et al. NEJM 2011;364:11-21
87 Cumulative Proportion of Patients with Primary End Point (%) PARADIGM-HF: Primary outcome Cardiovascular death or heart failure hospitalization HR: 0.80 (0.73, 0.87) p = Enalapril 1117 (n=4212) Sacubitril/valsartan (n=4187) Days after Randomization At risk Enalapril: Sacubitril/valsartan: McMurray, Packer et al. N Engl J Med 2014; 371(11):
88 Mild symptoms mild heart failure
89 PARADIGM-HF: Baseline Characteristics Sacubitril/valsartan (n=4187) Enalapril (n=4212) Age (years) 63.8 ± ± 11.3 Women (%) 21.0% 22.6% Ischemic cardiomyopathy (%) 59.9% 60.1% LV ejection fraction (%) 29.6 ± ± 6.3 NYHA functional class II / III (%) 71.6% / 23.1% 69.4% / 24.9% Systolic blood pressure (mm Hg) 122 ± ± 15 Heart rate (beats/min) 72 ± ± 12 N-terminal pro-bnp (pg/ml) 1631 ( ) 1594 ( ) B-type natriuretic peptide (pg/ml) 255 ( ) 251 ( ) History of diabetes 35% 35% Digitalis 29.3% 31.2% Beta-adrenergic blockers 93.1% 92.9% Mineralocorticoid antagonists 54.2% 57.0% CRT 7.0% 6.7% ICD 15% 15% McMurray et al. N Eng J Med 2014;371:
90 MAGGIC risk score 1. Age 2. Sex 3. Diabetes 4. COPD 5. BMI 6. Smoker 7. NYHA class 8. Diagnosis 18 months 9. Creatinine 10. SBP 11. LVEF 12. ACEi/ARB 13. Beta-blocker
91 MAGGIC Risk Score in PARADIGM-HF 40% chance of death at 3 years 50% chance of death at 3 years Simpson et al. J Am Coll Cardiol 2015;66:
92 Benefit of sacubitril/valsartan across MAGGIC risk score quintiles Enalapril Sacubitril/valsartan Simpson et al. J Am Coll Cardiol 2015;66:
93 RATE PER 100 PATIENT YEARS Benefit of sacubitril/valsartan across MAGGIC risk score quintiles 18 All-cause mortality Enalapril LCZ696 Sacubitril/valsartan QUINTILE OF RISK SCORE Simpson et al. J Am Coll Cardiol 2015;66:
94 HF-REF: The building blocks of therapy Digoxin CABG Tx VAD CRT ICD Ivabradine H-ISDN Beta-blocker ACEI/ARB MRA
95 HF-REF: The building blocks of therapy Digoxin CABG Tx VAD CRT ICD Ivabradine H-ISDN Beta-blocker ARNI MRA
96 Questions?
97
98 Back ups
99 Dementia and Neprilysin inhibition
100 Dementia and Neprilysin inhibition Cannon et al. Eur J Heart Fail (in press)
101 NYHA Class IV in PARADIGM-HF Sacubitril/valsartan better NYHA IV 0.71 (0.30, 1.69) Enalapril better Overall trial 0.80 (0.73, 0.87) Sacubitril/valsartan n/n (%) Enalapril n/n (%) Risk Ratio Sacubitril/valsartan vs. Enalapril NYHA IV Overall Safety Hypotension 3/33 (9.1) 3/27 (11.1) 0.95 (0.19, 4.69) 1.39 (1.26, 1.52) Renal impairment 4/33 (12.1) 3/27 (11.1) 1.25 (0.28, 5.60) 0.90 (0.81, 1.00) Hyperkalemia 5/33 (15.2) 6/27 (22.2) 0.71 (0.22, 2.32) 0.81 (0.72, 0.91) McMurray et al. Circulation 2016; 134(Supl1): A20000
102 Dose of enalapril in PARDIGM-HF Mean enalapril dose of enalapril in landmark studies of ACE inhibitors in HFREF CONSENSUS (1987): 18.4 mg 20 mg BID target dose SOLVD (1991): 16.6 mg 10 mg BID target dose V-HeFT II (1991): 15 mg 10 mg BID target dose Mean dose of enalapril in PARADIGM-HF = 18.9 mg daily Why not 20mg BID? More renal adverse events in CONSENSUS FDA mandated dose
103 Hypotension occurring during PARADIGM-HF Vardeny et al Circ Heart Fail. 2018;11:e004745
From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationSacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data,
Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data, praktische Erfahrungen michael.boehm@uks.eu M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin)
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationPractical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece
Practical considerations for the use of ARNI in CHF: clinical cases J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Disclosures: Research grants and honoraria for lectures from
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationWhat s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationSacubitril valsartan (Entresto ) for patients with symptomatic chronic heart failure
North Central London Joint Formulary Committee Sacubitril valsartan (Entresto ) for patients with symptomatic chronic heart failure North East and North Central London Position statement for the period
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationInitiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION SACUBITRIL/VALSARTAN (Entresto Novartis Pharmaceuticals) Indication: Heart Failure With Reduced Ejection Fraction Recommendation: The Canadian
More informationLearning Objectives. Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis
7:5 :5 am Update in Heart Failure SPEAKER Orly Vardeny, PharmD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Orly Vardeny, PharmD, MS: Advisory Board
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationHeart Failure Update. Chim Lang
Heart Failure Update Chim Lang Heart Failure Patient s Journey Acute Treat and stabilize Initiate monitoring Plan interventions Chronic Optimize drug and device therapy Manage Co-morbidities Subacute
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationECG in CRT patients & novel HF therapies. Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος
ECG in CRT patients & novel HF therapies Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received grants from Medtronic Is identification
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Evidence-Based Approaches to the Management of Heart Failure: Reducing Hospitalization and Improving Patient Outcomes Eldrin F. Lewis, MD, MPH Director of Cardiovascular Clerkship Brigham and Women s Hospital
More informationA New Future In Heart Failure (Should we reshuffle the deck?)
A New Future In Heart Failure (Should we reshuffle the deck?) DR. HEMANT SAHA, MD, MRCP(UK) AGA KHAN UNIVERSITY HOSPITAL, NAIROBI Disclosures Nothing to disclose. Objectives 1. Historical Perspectives
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than cancer
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 8 6 4 2 3.5 4.8 1. 1991 21 237 US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282,754 5-1% depending on severity
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationSummary 1. Comparative effectiveness
Cost-effectiveness of Sacubitril/Valsartan (Entresto) for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction. The NCPE has issued a recommendation regarding
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationEfficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial
European Journal of Heart Failure (2016) 18, 1228 1234 doi:10.1002/ejhf.580 RESEARCH ARTICLE Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection
More informationeplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd
eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration
ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication and Symptomatic HF despite ACEI/ARB and B-blocker therapy Bilateral renal artery stenosis Moderate/Severe
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationA new class of drugs for systolic heart failure: The PARADIGM-HF study
INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will describe the mechanism and use of angiotensin receptor-neprilysin inhibitors in heart failure MARWA A. SABE, MD, MPH Department of
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationChronic Heart Failure Therapies: Transforming the Landscape
Chronic Heart Failure Therapies: Transforming the Landscape Dr. Nadia Giannetti Chief of Cardiology Medical Director, Heart Failure and Heart Transplant Program McGill University Health Center Conflict
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More information